Core Viewpoint - The article discusses the recent funding activities of Senseonics Holdings, including a $50 million public offering and a $25 million private placement with Abbott, aimed at supporting the commercialization and development of its Eversense 365 continuous glucose monitoring (CGM) system [1][3]. Funding Structure and Use - Senseonics plans to raise approximately $50 million through a public offering, with an additional $25 million from Abbott, totaling $75 million (around 540 million RMB) [1][3]. - The funds will be allocated for commercial expansion of Eversense 365, product development, operational expenses, and debt repayment [3]. Strategic Implications of Abbott's Investment - Abbott will hold approximately 4.99% of Senseonics' common stock post-transaction, indicating a strategic partnership rather than a controlling stake [4]. - The investment allows Abbott to strengthen its position in the evolving CGM market, where competition is increasing from companies like Dexcom and Medtronic [4][6]. - Abbott's investment is seen as a proactive measure to counter potential market disruptions and to diversify its CGM product offerings [6][7]. Eversense 365 Overview - Eversense 365 is the first FDA-approved implantable CGM system that lasts for 365 days, significantly reducing the burden of daily management for patients [8][12]. - The system has a mean absolute relative difference (MARD) of 8.8%, with a 90% sensor function retention rate over a year [12][14]. Competitive Advantages of Eversense 365 - Eversense 365 offers a longer sensor life compared to traditional CGMs, which require frequent replacements every 10 to 14 days [13]. - The system features a removable transmitter, allowing for flexibility in daily activities and reducing skin irritation [15][17]. - It includes built-in alerts for high and low blood sugar levels, enhancing patient safety [16]. Future Product Development - Senseonics is developing two additional products, Gemini and Freedom, which aim to further enhance its product line and adapt to future market needs [11][19]. - These products are expected to play significant roles in closed-loop systems, providing Abbott with strategic options for future growth [7].

Core Viewpoint - Senseonics Holdings, Inc. is conducting a public offering of 100 million shares at $0.50 per share, aiming to raise $50 million before expenses [1] Group 1: Offering Details - The public offering is priced at $0.50 per share, with gross proceeds expected to be $50 million [1] - Underwriters have a 30-day option to purchase an additional 15 million shares at the same price [1] - The offering is set to close on May 19, 2025, pending customary closing conditions [1] Group 2: Underwriters - TD Cowen and Barclays are the joint book-running managers for the offering [2] - RBC Capital Markets and Lake Street are acting as bookrunners [2] Group 3: Concurrent Private Placement - Abbott Laboratories will purchase shares in a separate private placement at $0.50 per share, representing 4.99% of Senseonics' outstanding common stock post-offering [4] - The Concurrent Private Placement is expected to close on May 21, 2025, subject to the public offering's closing [4] Group 4: Use of Proceeds - The net proceeds from both the public offering and the Concurrent Private Placement will be used to fund the launch of Eversense 365, ongoing product development, working capital, and general corporate purposes [5] Group 5: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems for diabetes management [7] - The company's products include Eversense® 365 and Eversense® E3, which feature a small sensor that communicates glucose data to a mobile app every 5 minutes [7]

Core Viewpoint - Senseonics Holdings, Inc. has initiated an underwritten public offering of its common stock, with a potential additional 15% of shares available for underwriters to purchase [1][2]. Group 1: Offering Details - The public offering is subject to market conditions and will be made under a "shelf" registration statement filed with the SEC [3]. - TD Cowen and Barclays are the joint book-running managers for the offering, with RBC Capital Markets and Lake Street acting as bookrunners [2]. - A preliminary prospectus supplement will be filed with the SEC and will be accessible on their website [3]. Group 2: Concurrent Private Placement - Abbott Laboratories has agreed to purchase up to $25 million of Senseonics' common stock in a separate private placement, contingent on the public offering's closing [4]. - The net proceeds from both the public offering and the concurrent private placement will be used to support the launch of Eversense 365, ongoing product development, and general corporate purposes [5]. Group 3: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems for diabetes management, with products like Eversense® 365 and Eversense® E3 [8]. - The company's CGM systems feature a small sensor that is implanted under the skin and communicates glucose data to a mobile app every 5 minutes [8].

Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this medical technology company would post a loss of $0.03 per share when it actually produced a loss of $0.02, delivering a surprise of 33.33%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Senseonics, which b ...

Financial Data and Key Metrics Changes - In Q1 2025, net revenue grew 24% to $6.3 million compared to $5 million in the prior year period [18] - U.S. revenue for Q1 was $4.5 million, while revenue outside the U.S. was $1.8 million [18] - Gross profit increased to $1.5 million from $300,000 in the prior year, driven by increased margins on the Eversense three sixty five product [21] - Net loss decreased to $14.3 million or $0.02 loss per share from a net loss of $18.9 million or $0.03 loss per share in the prior year [23] Business Line Data and Key Metrics Changes - The Eversense three sixty five continuous glucose monitor (CGM) is positioned as a significant product, with a focus on integration with automated insulin delivery systems [7][9] - The company is working on expanding its Eversense three sixty five offering and has filed for CE Mark approval, anticipating a European launch in the second half of 2025 [12] - The consignment program continues to show strong utilization, contributing approximately 13% of revenue in Q1 [20] Market Data and Key Metrics Changes - The company is seeing positive responses from both U.S. and international markets, with expectations for significant growth in patient adoption [36] - The Medicare reimbursement update is expected to facilitate broader adoption of the Eversense three sixty five sensor [40] - The company anticipates doubling its global patient base in 2025 compared to 2024, with revenue expected to be approximately one-third in the first half and two-thirds in the second half of the year [26] Company Strategy and Development Direction - The company aims to transform diabetes care through technological advancements and partnerships, focusing on the integration of its CGM with insulin delivery systems [7][9] - Collaborations with companies like Sequel and Sweet Spot are part of the growth strategy to enhance patient care and streamline monitoring processes [9][10] - The company plans to continue developing its pipeline products, GEMINI and Freedom, to improve patient experience and expand its market offerings [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the launch metrics and revenue numbers, indicating a positive trajectory for the Eversense three sixty five product [29] - The company is closely monitoring the evolving tariff situation and expects to mitigate any negative impacts on gross profit margins [27] - Full-year 2025 global net revenue is projected to be approximately $34 million to $38 million, reflecting confidence in the product's market acceptance and growth potential [25] Other Important Information - The company received gross proceeds of approximately $27 million from the sale of common stock, extending its cash runway into mid-2026 [24] - As of March 31, 2025, cash and cash equivalents totaled $64.6 million, with total principal debt outstanding reduced to $35 million [23] Q&A Session Summary Question: Guidance despite Mercy contract pause - Management noted that early launch metrics for Eversense three sixty five are positive, and while the Mercy contract pause is a factor, the overall trajectory remains strong [34][36] Question: Direct-to-consumer (DTC) efforts - The company is focusing on social media channels like Facebook, TikTok, and Instagram for DTC marketing, targeting insulin users, particularly in the Medicare population [38][40] Question: Twist integration timeline - Management confirmed that integration work is ongoing, with verification and validation of the system expected to be completed by Q3 [44][46] Question: Update on commercial plans converting to three sixty five sensor - Management expects the majority of commercial plans to convert by the end of the year, with significant progress already made [47][48]

Financial Data and Key Metrics Changes - In Q1 2025, net revenue grew 24% to $6.3 million compared to $5 million in the prior year period [16] - U.S. revenue for Q1 was $4.5 million, while revenue outside the U.S. was $1.8 million [16] - Gross profit increased to $1.5 million from $300,000 in the prior year, driven by improved margins on the Eversense three sixty five product [19] - Net loss decreased to $14.3 million or $0.02 loss per share, compared to a net loss of $18.9 million or $0.03 loss per share in Q1 2024 [21] - Cash, restricted cash, and cash equivalents totaled $64.6 million as of March 31, 2025 [21] Business Line Data and Key Metrics Changes - The Eversense three sixty five product is expected to be the single product offering by the end of 2025, enhancing global supply chain synergies [11] - Approximately 13% of revenue flowed through the office consignment program, with over 100 healthcare providers participating [18] - The company is transitioning reimbursement from 180 days to 365 days for Eversense, with many payers already transitioning their coverage [12] Market Data and Key Metrics Changes - The company anticipates doubling the global patient base in 2025 compared to 2024, with revenue expected to be approximately one-third in the first half and two-thirds in the second half of the year [23] - The European launch of Eversense three sixty five is planned for the second half of 2025, pending regulatory approval [11][22] Company Strategy and Development Direction - The company is focused on transforming diabetes care through technological advancements, including collaborations with Sequel and Sweet Spot [6][7] - The integration of Eversense three sixty five with Sequel's Twist automated insulin delivery system is seen as a significant step forward [6] - Continued development of pipeline products, GEMINI and Freedom, is a priority, with plans to submit an IDE for a pivotal study by year-end [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early launch metrics for Eversense three sixty five, indicating strong interest and conversion rates [32] - The company expects to mitigate any negative impacts from tariffs on gross profit margins through operational changes and industry exemptions [24] - Full-year gross margins are projected to be between 25% and 30%, with expectations for steady increases each quarter in 2025 [24] Other Important Information - The company received gross proceeds of approximately $27 million from the sale of common stock, extending its cash runway into mid-2026 [22] - All preferred stock was converted into common stock, impacting the diluted earnings per share calculation [21] Q&A Session Summary Question: Guidance despite Mercy contract pause - Management noted that early launch metrics for Eversense three sixty five are positive, and while the Mercy contract pause is a concern, the overall trajectory remains strong [30][32] Question: Direct-to-consumer (DTC) efforts - The company is focusing on social media channels like Facebook, TikTok, and Instagram for DTC marketing, targeting insulin users, particularly in the Medicare population [36][38] Question: Twist integration timeline - Integration work is ongoing, with most efforts focused on verification and validation of the integrated system, expected to be completed by Q3 [41][43] Question: Update on commercial plans for reimbursement - Management expects the majority of commercial plans to convert to the 365-day sensor by the end of the year, with significant progress already made [44][45]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37717 Senseonics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2025 SENSEONICS HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37717 47-1210911 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 20451 Seneca Meadows Parkway Germantown, MD 20876-7005 (Address of ...

Core Insights - Senseonics Holdings, Inc. reported a first quarter revenue of $6.3 million, representing a year-over-year growth of 24% from $5.0 million in Q1 2024 [4] - The company has partnered with Sequel to integrate its twiist™ automated insulin delivery system with the Eversense® 365 continuous glucose monitor, with a launch expected in Q3 2025 [1][9] - The company aims to improve access and flexibility for diabetes patients through its Eversense platform, with significant milestones achieved in reimbursement and product development [3] Financial Performance - Total revenue for Q1 2025 was $6.3 million, with U.S. revenue at $4.5 million and international revenue at $1.8 million, compared to $3.7 million and $1.3 million respectively in Q1 2024 [4] - Gross profit for Q1 2025 was $1.5 million, up from $0.3 million in Q1 2024, driven by increased margins on the 365-day product [5] - The net loss for Q1 2025 was $14.3 million, a reduction from a net loss of $18.9 million in Q1 2024, attributed to improved gross profit margins and reduced R&D costs [7] Expense Management - Selling, general and administrative expenses decreased by $0.4 million year-over-year to $7.7 million, primarily due to lower personnel costs and consulting fees [5] - Research and development expenses decreased by $3.1 million year-over-year to $7.3 million, mainly due to reduced spending on clinical studies following the completion of trials for the 365-day product [6] Future Outlook - The company expects full-year 2025 global net revenue to be approximately $34-38 million, anticipating a doubling of its global patient base [8] - Gross margins are projected to increase throughout 2025, with expectations of reaching between 25% and 30% for the full year [10] - Cash used in operations for 2025 is expected to be between $50 million and $60 million [10]

Core Viewpoint - Senseonics Holdings, Inc. is set to release its first quarter 2025 financial results on May 8, 2025, after market close, indicating ongoing developments in its financial performance and product offerings [1]. Group 1: Financial Results Announcement - The company will announce its first quarter 2025 financial results after market close on May 8, 2025 [1]. - A conference call to discuss the financial performance will take place at 4:30 p.m. (Eastern Time) on the same day, which will also be available via webcast [2]. Group 2: Company Overview - Senseonics is a medical technology company focused on developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems for diabetes management [3]. - The company's CGM systems, Eversense 365 and Eversense E3, feature a small sensor that is implanted under the skin and communicates with a smart transmitter, sending glucose data to a mobile app every 5 minutes [3].